Genetic basis of antigenic variation of SAT3 foot-and-mouth disease virus by Maake, Lorens et al.
ORIGINAL RESEARCH
published: 08 September 2020
doi: 10.3389/fvets.2020.00568
Frontiers in Veterinary Science | www.frontiersin.org 1 September 2020 | Volume 7 | Article 568
Edited by:
Wilna Vosloo,
Commonwealth Scientific and
Industrial Research Organisation
(CSIRO), Australia
Reviewed by:
Begona Valdazo-Gonzalez,
Lab Services Ltd, United Kingdom
Suresh H. Basagoudanavar,
ICAR-Indian Veterinary
Research Institute, India
Donald King,
Pirbright Institute, United Kingdom
*Correspondence:
Francois F. Maree
mareef@arc.agric.za
Specialty section:
This article was submitted to
Veterinary Infectious Diseases,
a section of the journal
Frontiers in Veterinary Science
Received: 20 April 2020
Accepted: 16 July 2020
Published: 08 September 2020
Citation:
Maake L, Harvey WT, Rotherham L,
Opperman P, Theron J, Reeve R and
Maree FF (2020) Genetic Basis of
Antigenic Variation of SAT3
Foot-And-Mouth Disease Viruses in
Southern Africa. Front. Vet. Sci. 7:568.
doi: 10.3389/fvets.2020.00568
Genetic Basis of Antigenic Variation
of SAT3 Foot-And-Mouth Disease
Viruses in Southern Africa
Lorens Maake 1,2, William T. Harvey 3, Lia Rotherham 1, Pamela Opperman 1,4,
Jacques Theron 2, Richard Reeve 3 and Francois F. Maree 1,2*
1 Vaccine and Diagnostic Development Programme, Onderstepoort Veterinary Institute, Agricultural Research Council,
Pretoria, South Africa, 2Department of Biochemistry, Genetics and Microbiology, Faculty of Agricultural and Natural Sciences,
University of Pretoria, Pretoria, South Africa, 3 Boyd Orr Centre for Population and Ecosystem Health, Institute of Biodiversity,
Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow,
United Kingdom, 4Department of Animal Production Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria,
South Africa
Foot-and-mouth disease (FMD) continues to be a major burden for livestock owners in
endemic countries and a continuous threat to FMD-free countries. The epidemiology and
control of FMD in Africa is complicated by the presence of five clinically indistinguishable
serotypes. Of these the Southern African Territories (SAT) type 3 has received limited
attention, likely due to its restricted distribution and it being less frequently detected.
We investigated the intratypic genetic variation of the complete P1 capsid-coding region
of 22 SAT3 viruses and confirmed the geographical distribution of five of the six SAT3
topotypes. The antigenic cross-reactivity of 12 SAT3 viruses against reference antisera
was assessed by performing virus neutralization assays and calculating the r1-values,
which is a ratio of the heterologous neutralizing titer to the homologous neutralizing
titer. Interestingly, cross-reactivity between the SAT3 reference antisera and many SAT3
viruses was notably high (r1-values >0.3). Moreover, some of the SAT3 viruses reacted
more strongly to the reference sera compared to the homologous virus (r1-values>1). An
increase in the avidity of the reference antisera to the heterologous viruses could explain
some of the higher neutralization titers observed. Subsequently, we used the antigenic
variability data and corresponding genetic and structural data to predict naturally
occurring amino acid positions that correlate with antigenic changes. We identified four
unique residues within the VP1, VP2, and VP3 proteins, associated with a change in
cross-reactivity, with two sites that change simultaneously. The analysis of antigenic
variation in the context of sequence differences is critical for both surveillance-informed
selection of effective vaccines and the rational design of vaccine antigens tailored for
specific geographic localities, using reverse genetics.
Keywords: foot-and-mouth disease (FMD), Southern African Territory (SAT) type 3, antigenic, cross-reactivity,
antigenic matching, phylogeny, virus neutralization test
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HIGHLIGHTS
- Phylogenetic relationships of the capsid-coding region of
SAT3 viruses confirmed the geographical distribution of the
southern African topotypes.
- Cross-reactivity between SAT3 reference antisera and SAT3
viruses is notably high.
- Avidity could explain some of the higher cross-
reactivity observed.
- Unique amino acid residues may be associated with a change
in cross-reactivity.
INTRODUCTION
Foot-and-mouth disease (FMD) continues to be a major burden
for livestock owners in endemic countries (1). The occurrence
of FMD negatively impacts on the livelihoods of local farmers
due to its effects on productivity, food insecurity and losses of
income, but also have damaging consequences on international
trade in livestock and animal products. The disease is widely
distributed in Africa, Asia, and South America where FMD
is regarded as endemic. FMD outbreaks particularly affect
vulnerable individuals, such as women and children since ∼75%
of livestock in Africa are raised under the communal smallholder,
communal-grazing or pastoral systems that sustain livelihoods of
these groups (2, 3). Controlling FMD at its source is therefore
a shared interest between endemic and free countries (4). The
epidemiology of FMD in sub-Saharan Africa is unique due to the
presence of the South African Territories (SAT) serotypes that are
almost exclusively endemic, and its continuous maintenance in
wildlife (5–7). Therefore, FMD control in livestock is dependent,
in part, on an understanding of pathogenesis, persistence, and
transmission from African buffalo (Syncerus caffer) (7).
Clinically indistinguishable FMD viruses (FMDV) belonging
to the SAT serotypes are maintained in buffalo, but differ
from each other with respect to their geographic distribution,
incidence, outer capsid-coding sequence and antigenicity. SAT2
is the most widely distributed in Africa and is also the serotype
most often associated with outbreaks in cattle in southern Africa,
followed by SAT1 and then SAT3 (8–10). However, viruses
of the SAT1 serotype is most frequently isolated from buffalo
(7, 11). Viruses belonging to the SAT3 serotype have the most
restricted distribution and essentially occur in southern Africa
and in the south-western region of Uganda (12, 13). The SAT3
serotype is also less frequently detected in African buffalo (12).
In South Africa, in the Kruger National Park, a SAT3 outbreak
occurred in 1958/59 where it involved wildebeest (Connochaetes
taurinus), kudu (Tragelaphus strepsiceros) and sable antelope
(Hippo tragus niger) (14) and was also detected in Mozambique.
Other outbreaks were detected in cattle in Limpopo (Giyani)
during 1979/80 (15), in Phalaborwa during 2002 affecting buffalo,
in Thulamela during 2006 and in the Kruger National Park
(Pafuri) during 2008 affecting impala (Aepyceros melampus) as
well. The 1979/80 outbreak in Giyani lasted for 9 months and
was the longest SAT3 outbreak reported to date (9). Neighboring
southern African countries also experienced SAT3 outbreaks
during similar times with the most recent outbreaks reported
in livestock in Namibia in 2011, Zimbabwe in 1999 and 2013,
Zambia in 2015 and 2017, and Mozambique in 2016–2017
(Records of the OIE).
Phylogenetic reconstruction of the partial VP1-coding
nucleotide sequence from SAT3 viruses has revealed at least six
(I–VI) distinct topotypes. Amongst them, topotypes I–IV occur
in southern Africa, whereas topotypes V and VI are unique
to Uganda (12, 13). The SAT3 viruses belonging to different
topotypes differed by 20% or more in complete nucleotide
sequence alignments of the VP1-coding region (12). Studies
comparing genetic variation and serological cross-reactivity have
shown that SAT1 and SAT2 viruses from different topotypes
are generally antigenic poorly related (16, 17). However, similar
studies have not yet been undertaken for SAT3 viruses.
Studies focusing exclusively on SAT3 viruses are lacking.
Limited studies have been performed to determine the genetic
diversity of SAT3 viruses, but these studies were primarily based
on partial VP1 sequences. Here, we assessed the intratypic SAT3
genetic variation of the VP1, VP2, VP3, and VP4 capsid proteins
and antigenic cross-reactivity within the southern African SAT3
viruses. The analysis of antigenic variation is critical to allow
proper vaccine selection or the design of vaccine antigens tailored
for specific geographic localities, using reverse genetics.
MATERIALS AND METHODS
Cells and Viruses
Instituto Biologico Renal Suino-2 cells (IB-RS-2) and primary
pig kidney (PPK) cells were maintained and propagated in
Roswell Park Memorial Institute (RPMI) medium (Sigma-
Aldrich) supplemented with 10% (vol/vol) fetal bovine serum
(FBS; Delta Bioproducts) and a 1µg/ml amphotericin B and 0.5
mg/ml gentamycin mixture (Gibco) (18).
Twelve SAT3 viruses, collected from buffalo or cattle during
1990–2010 in southern Africa, were sequenced and used for
genetic and antigenic analysis and an additional ten SAT3
P1 sequences available in GenBank were included for the
genetic analysis. The viruses form part of the virus databank
of the Agricultural Research Council-Onderstepoort Veterinary
Research Institute (ARC-OVR), Transboundary Animal Diseases
(TAD) Biosafety Level 3 (BSL-3) laboratory (South Africa). The
species, which the viruses were isolated from, the country of
origin, and year of isolation are summarized in Table 1. The
viral isolates were initially passaged on PPK cells, prior to
propagation on IB-RS-2 cells and harvested when maximum
cytopathic effect (CPE) was observed or after 48 h. All viruses
were titrated to determine the tissue culture infectious dose at
50% (TCID50). Virus growth medium (VGM) was prepared with
RPMI supplemented with 5% (vol/vol) FBS and 1% (vol/vol)
antibiotics/antimycotic mixture (Gibco). The SAT3/KNP/10/90,
SAT3/SAR/1/06 (topotype I), and SAT3/BOT/6/98 (topotype II)
viruses were selected as reference material for the preparation
of antisera.
Virus Titrations
The viral titers were determined in flat-bottomed microtiter
plates (Nunc). Briefly, 0.5 log10 dilutions of the virus stocks
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TABLE 1 | List of SAT3 viruses used in the current study including species of isolation, passage history, year of isolation, and country of isolation.
SAT3 virus GenBank accesion numbers Species Passage history Year Country of isolation References
KNP/10/90 AF286347 Buffalo PK1RS2 1990 South Africa This study
KNP/2/03 MK415738 Buffalo PK1RS2 2003 South Africa This study
KNP/6/08 MK415735 Buffalo PK1RS3 2008 South Africa This study
KNP/14/96 MK415741 Buffalo PK1RS2 1996 South Africa This study
KNP/8/02 MK415739 Buffalo PK1RS1 2002 South Africa This study
KNP/1/03 MK415737 Buffalo PK1RS2 2003 South Africa This study
KNP/1/08 MK415734 Buffalo PK1RS2 2008 South Africa (7)
SAR/57/59 AY593850 – – 1959 South Africa (19)
SAR/14/01 MK415740 Buffalo PK1RS2 2001 South Africa This study
SAR/1/06 MK415736 Buffalo PK1RS2 2006 South Africa This study
ZIM/4/81 KX375417 – – 1981 Zimbabwe (20)
ZIM/6/91 KM268901 – – 1991 Zimbabwe (21)
ZIM/11/94 MK415743 Buffalo PK1RS5 1994 Zimbabwe This study
BOT/6/98 MK415742 Buffalo PK1RS2 1998 Botswana This study
KEN/11/60 AY593852 – – 1960 Kenya (19)
BEC/20/61 AY593851 – – 1961 Botswana (19)
BEC/1/65 AY593853 – – 1965 Botswana (19)
ZIM/5/91 MK415745 Buffalo PK1RS5 1991 Zimbabwe This study
ZAM/5/93 MK415744 Buffalo PK1RS2 1993 Zambia This study
ZAM/4/96 DQ009741 – – 1996 Zambia (16)
UGA/2/97 DQ009742 – – 1997 Uganda (16)
UGA/1/13 KJ820999 – – 2013 Uganda (13)
were titrated into 96-well microtitre plates (Nunc), followed
by addition of 3 × 105 IB-RS-2 cells per well. Plates were
incubated at 37◦C with continuous CO2 influx. At 72 h post-
inoculation the remaining intact cells were stained with 1%
(wt/vol) methylene blue in 10% (vol/vol) formalin. The plaques
were counted to calculate virus titers, which were expressed as
tissue culture infectious dose 50% (TCID50) according to the
method of Kärber (22).
RNA Extraction, cDNA Synthesis, PCR
Amplification, and Sequencing
Viral RNA was extracted from infected cell culture supernatant
using the QIAamp viral RNA mini extraction kit (Qiagen)
and used as template for cDNA synthesis (23). First-strand
cDNA synthesis was performed using the SuperScript R© III
First-Strand Synthesis System (Invitrogen) and the genome-
specific oligonucleotide 2B (24) following the manufacturer’s
recommendations. The FMDV ca. 3.0 kb Leader/capsid-
coding region was PCR amplified using the Expand High
Fidelity PCR system (Roche) and flanking oligonucleotides
NCR (5′-TAACAAGCGACACTCGGGATCT-3′) and WDA
(5′-GAAGGGCCCAGGGTTGGACTC-3′) (25). Amplicons
were purified from an agarose gel with the QIAquick R© Gel
Extraction Kit (Qiagen). Sequencing of the amplicons was
performed using the ABI PRISMTM BigDye Terminator Cycle
Sequencing Ready Reaction Kit v3.0 (Perkin Elmer Applied
Biosystems) and resolved on an ABI PRISM 3100 Genetic
Analyser (Applied Biosystems). The sequences were assembled
using Sequencher 5.1 (GeneCodes). The GenBank accession
numbers of the capsid-coding sequences are shown in Table 1.
The nucleotide sequences were aligned using CLUSTAL_X (26)
and phylogenetic trees were constructed using MEGA (27).
Preparation of Bovine Serum
Convalescent sera were obtained from cattle infected with
the respective SAT3 reference viruses (SAT3/KNP/10/90,
SAT3/SAR/1/06, and SAT3/BOT/6/98), 28 days post-infection
(dpi). Groups of five cattle were inoculated intradermoligually
with 1ml of 104 TCID50 per ml of either of the reference viruses.
Cattle were housed in the biosafety level 3 stables at the ARC-
OVR, TAD. All procedures were approved by the ARC-OVR
Animal Ethics Committee (Ethics approval number AEC18.11)
according to national animal welfare standards and performed
with the permission of the Department of Agriculture, Forestry,
and Fisheries (Act 35 of 1984).
Sera collected from each infected cattle were inactivated
at 56◦C for 30min. Inactivated sera from the five cattle for
each group were pooled and the pooled sera were used in
subsequent experiments.
Virus Neutralization Test
Antigenic cross-reactivity of FMDV against the convalescent
animal sera was determined using the virus neutralization test
(VNT) according to the World Organization for Animal Health
(OIE) Manual of Diagnostic Tests and Vaccines for Terrestrial
Animals (28). Briefly, the test serum was diluted 2-fold in
VGM using 96-well microtitre (Nunc) plates, starting with a 1/8
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dilution, and mixed with a virus suspension containing ∼100
TCID50 per well. After 1 h of incubation at 37
◦C, 3 × 105 IB-
RS-2 cells were added to each well and incubated for a further
72 h at 37◦C in a humid atmosphere containing 5% CO2. Cell-
only controls were added to each plate and a virus titration
control and positive serum control (cells, virus, and positive
reference serum) were performed on each day. Plates were
analyzed microscopically and colorimetrically for CPE and 50%
end-point serum titers were calculated according to the method
of Kärber (22). Virus neutralization titers were expressed as the
log10 of the reciprocal serum dilution that protected the cells in
50% of the inoculated wells. All VNTs were performed at least
three times. One-way antigenic relationships (r1-value) of the
field virus isolates relative to the reference viruses were calculated,
and expressed as the ratio between heterologous and homologous
serum titer. The criteria of the OIE Manual (28) were applied
for interpreting the antigenic relationships. Briefly, r1-values
between 0 and 0.29 indicated significant antigenic variation from
the reference viruses, and values of ≥0.30 demonstrated that the
reference and field viruses are sufficiently antigenically similar.
Virus Purification
BHK-21 cell were seeded, based on cell counts performed
using a haemocytometer and tryphan blue staining, into
8 × 750 cm2 plastic roller bottles (Corning) to obtain
confluent monolayers. Confluent BHK-21 cell monolayers were
infected at an multiplicity of infection (MOI) of 5–10 pfu/cell
with SAT3/KNP/10/90, SAT3/BOT/6/98, SAT3/SAR/1/06,
SAT3/KNP/14/96, or SAT3/SAR/14/01 in Glasgow’s Minimal
Essential Medium (GMEM) supplemented with 10% (vol/vol)
tryptose phosphate broth (TPB), 3% (vol/vol) lactalbumin
hydrolysate solution, 1% (vol/vol) FBS, 1% (vol/vol) antibiotic-
antimycotic solution, and 25mM HEPES buffer. Following
incubation for 14–16 h at 37◦C, the cells were lysed by addition
of 10% (vol/vol) Nonidet P-40 and 0.5M EDTA (pH > 7.4). The
virus particles were recovered and concentrated from the lysed
cell supernatants as described by Opperman et al. (29). The 146S
virus particles were purified on a 10–50% (wt/vol) sucrose density
gradient (SDG), prepared in TNE buffer (50mM Tris [pH 7.5],
150mM KCl, 10mM EDTA), as described previously (30). Peak
sucrose fractions corresponding to 146S virion particles were
pooled and the amount of antigen was calculated (31).
Single Dilution Avidity ELISA (sd A-ELISA)
The protocol was adapted from Lavoria et al. (32). Briefly,
Maxisorp ELISA plates were coated, in duplicate, overnight at
4◦C with 200 ng of sucrose density gradient (SDG)-purified
virus in 50mM carbonate/bicarbonate buffer (pH 9.6). The plates
were washed with phosphate-buffered saline (PBS) containing
0.05% (vol/vol) Tween-20 (PBS-0.05%T) and blocked at 37◦C
for 1.5 h with blocking buffer [PBS, 20% (vol/vol) FCS, 0.002%
(wt/vol) thimerosal, and 0.1% (wt/vol) phenol red] and washed.
The reference sera were diluted 1:40 in blocking buffer, added to
the plates and incubated at 37◦C for 1 h. The negative control
sera consisted of a pool of five negative bovine sera. The plates
were washed three times with PBS-0.05%T and then 4M urea
in PBS was added to one plate and PBS was added to the
remaining plate. Following incubation at room temperature
for 20min, the plates were washed again before the FMDV-
specific antibodies were detected with horseradish peroxidase-
labeled anti-bovine conjugate (Sigma-Aldrich), diluted 1:20,000
in blocking buffer (29). The ELISA plates were developed using
a substrate/chromogen solution, consisting of 4mM 3,3′,5,5′-
tetramethylbenzidine (Sigma-Aldrich) in substrate buffer (0.1M
citric acid monohydrate, 0.1M tri-potassium citrate; pH 4.5)
and 0.015% (vol/vol) of H2O2. The color reaction was stopped
after 10min with 1M H2SO4 and the optical density (OD) was
read at 450 nm using a Labsystems Multiscan Plus photometer.
Mean OD values of samples and controls were corrected by
subtracting mean blank OD values (cOD). The avidity index
(AI) was calculated as described previously (32). Briefly, AI% =
(cOD sample with urea/cOD sample without urea) × 100. AI
were compared using one-way analysis of variance (ANOVA) and
Benferroni’s multiple comparison test (33) with a 95% confidence
interval (CI) of difference; p-value <0.5 indicated significance
binding. The analysis was performed using GraphPad Prism
v5.03 for Windows (GraphPad Software, Inc.).
Statistical Analysis of Gene Sequences and
Virus Neutralization Titers
To identify genetic predictors of antigenic variation, amino acid
substitutions between reference viruses and test viruses were
tested using a model fitted to geometric (log2) VN titers, while
accounting for phylogenetic relationships and non-antigenic
variation in VN titers that can be attributed to day-to-day
variability in tests performed on different dates. To prevent
false support for substitutions that arise due to the evolutionary
process, phylogenetic information was included in the model
(17). A phylogenetic tree was reconstructed from aligned capsid
nucleotide sequences using PhyML v3.0 (34). The general time
reversible model with a proportion of invariant sites and a
gamma distribution describing among-site rate variation (GTR+
I+Γ4) was identified as the best model of nucleotide substitution
using jModelTest v2.1.10 (35). Each combination of reference
and test virus is separated by a unique combination of branches of
the phylogeny. Phylogeny branches separating reference and test
viruses were tested as correlating with antigenic change expressed
in lower VN titers. In addition, phylogenetic terms associated
with changes in immunogenicity were identified (branches).
The optimal combination of amino acid position variables and
phylogenetic variable was identified using a sparse hierarchical
Bayesian model where each variable is associated with parameter
estimate and in addition, a binary indicator variable that
determines inclusion (1) or exclusion (0) in the model (36). The
posterior mean of each indicator variable provides an estimate
for the inclusion probability for each variable. Additionally, the
model was used to estimate the proportion of all variables tested
that should be included in an optimal model. Conditional effect
sizes (coefficient estimated for a variable when present in the
model, i.e., when associated indicator variable= 1) were mapped
to branches of the phylogeny and visualized alongside a heatmap
showing VN titers using the ggtree R package (37). Separately,
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TABLE 2 | Comparison of the number of variable amino acids in a pairwise alignment of the structural proteins (P1 polypeptide) and r1-values between reference viruses
and test viruses.
Strain Topotypea SAT3/KNP/10/90 SAT3/SAR/01/06 SAT3/BOT/06/98
Variable amino acidb r1-value
c Variable amino acidb r1-value
c Variable amino acidb r1-value
c
SAT3/KNP/10/90 I 0 1 38 1.78 57 1.28
SAT3/SAR/14/01 I 40 0.65 44 1.46 67 1.16
SAT3/ZIM/6/91 I 36 – 37 – 61 –
SAT3/KNP/2/03 I 33 0.39 33 0.6 56 0.45
SAT3/KNP/8/02 I 28 0.21 32 0.41 54 0.38
SAT3/SAR/1/06 I 38 <0.2 0 1 63 0.87
SAT3/KNP/1/03 I 38 <0.2 50 <0.2 64 0.39
SAT3/KNP/1/08 I 39 – 37 – 60 –
SAT3/SAR/57/59 I 42 – 41 – 66 –
SAT3/KNP/14/96 I 40 1.09 43 1.67 55 1.32
SAT3/KNP/6/08 I 36 0.73 42 1 53 1
SAT3/ZIM/4/81 I 34 – 40 – 61 –
SAT3/ZIM/11/94 II 51 0.48 56 1 46 0.83
SAT3/KEN/11/60 II 65 – 77 – 50 –
SAT3/BEC/20/61 II 66 – 78 – 51 –
SAT3/BEC/1/65 II 57 – 61 – 39 –
SAT3/BOT/6/98 II 57 0.6 63 2.24 0 1
SAT3/ZIM/5/91 III 59 0.27 64 0.54 69 0.64
SAT3/ZAM/4/96 IV 61 – 74 – 62 –
SAT3/ZAM/5/93 IV 56 0.97 70 0.7 58 0.94
SAT3/UGA/2/97 VI 118 – 119 – 113 –
SAT3/UGA/1/13 VI 122 – 128 – 124 –
aThe topotypes classification is based on the VP1 phylogeny proposed by Vosloo et al. (38) and Bastos et al. (12).
bPairwise alignment was performed for the complete P1 polypeptide of 741 amino acids.
cr1-values higher than 1 are indicated in bold and those values lower than 0.3 in italics. The homologous r1-values are highlighted in light gray.
“–” VNTs were not performed and sequences of these viruses were retrieved from GenBank.
a two-dimensional hierarchical clustering of reference and test
viruses was performed and visualized as a heatmap.
RESULTS
Antigenic Diversity Among SAT3 Viruses in
Southern Africa
We applied one-way antigenic relationships (r1-values),
measured by VNTs, to investigate the antigenic variability of
viruses belonging to the SAT3 serotype in southern Africa.
SAT3 viruses showed a significant degree of cross-reactivity
to the sera of the SAT3 reference viruses (SAT3/SAR/1/06 and
SAT3/BOT/6/98) (Table 2). At least 92% (n = 11) and 100%
(n = 12) of the SAT3 viruses showed r1-values ≥0.3 to the
SAT3/SAR/1/06 (topotype I) and SAT3/BOT/6/98 (topotype II)
sera, respectively. However, one of the viruses in topotype I,
SAT3/KNP/1/03, had an r1-value of <0.2 when tested against
SAT3/SAR/1/06, but cross-reacted with SAT3/BOT/6/98 antisera
with an r1-value of 0.39. Cross-reactivity to the SAT3/KNP/10/90
(topotype I) reference sera indicated that 67% (n = 8) of the
viruses were neutralized by the sera with an r1-value above
0.3. Interestingly, three viruses showed r1-values >1.0 against
SAT3/BOT/6/98 antisera and four viruses had a similar high
cross-reactivity to the SAT3/SAR/1/06 antisera, one of which
was as high as 2.24. We then investigated whether the higher
neutralization titers of these viruses (KNP/10/90, SAR/14/01,
KNP/14/96 and BOT/6/98) were as a result of increased avidity
of the antisera to the particular viruses.
The avidity index of the SAT3/BOT/6/98 and SAT3/SAR/1/06
bovine antisera against the SAT3 viruses with r1-values >1.0
(SAT3/KNP/10/90, SAT3/SAR/14/01, SAT3/KNP/14/96), and the
homologous viruses is shown in Figure 1. The avidity index
of the SAT3/KNP/10/90 (AI = 72%) and SAT3/SAR/14/01 (AI
= 67%) viruses to the SAT3/SAR/1/06 antisera was higher
than the avidity to the homologous virus (AI = 56%), albeit
statistically insignificant (p> 0.05) (Figure 1A). Avidity values of
<25% were observed for SAT3/BOT/6/98 and SAT3/KNP/14/96
viruses to the SAT3/SAR/1/06 antisera. In contrast, antibodies
in SAT3/BOT/6/98 antisera bound with high avidity to the
SAT3/KNP/10/90 (AI = 65%; p < 0.01), SAT3/SAR/14/01 (AI
= 72%; p < 0.001), and SAT3/SAR/1/06 (AI = 47%; p > 0.05)
viruses, while the avidity against the SAT3/KNP/14/96 (AI =
11%) and the homologous virus, SAT3/BOT/6/98 (AI = 28%),
was lower (Figure 1B).
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FIGURE 1 | Avidity index of the SDG-purified SAT3 viruses SAT3/SAR/1/06, SAT3/BOT/6/98, SAT3/KNP/10/90, SAT3/SAR/14/01, and SAT3/KNP/14/96, to the
bovine antisera raised against SAT3/SAR/1/06 (A) and SAT3/BOT/6/98 (B) are indicated. The data are means ± SD of quadruplicate experiments. **p < 0.01, ***p <
0.001 at 95% CI.
Genetic Variation in the Capsid Proteins of
SAT3 Viruses
The intratypic nucleotide variation of the SAT3 P1 region was
calculated to be 45.6% (n = 22) and is comparable to the
intratypic variation reported for SAT1 (47.3%; n = 20) and
SAT2 (48.9%; n = 23) viruses, but higher than types A (42.5%;
n = 50) and O (38.2%; n = 41) (16, 19). The nucleotide and
amino acid variation in a complete alignment of the SAT3
capsid proteins and coding region is summarized in Table 3.
With the exception of SAT3/KNP/10/90, the P1 region of
SAT3 viruses was 2,220 nucleotides in length and encodes 740
amino acids representing the four structural proteins. The VP1-
coding region of SAT3/KNP/10/90 contains a three-nucleotide-
insertion between nucleotides 252 and 253, which translates to
an additional amino acid (lysine, K) in the βD-βE loop of the
VP1 protein. Overall, in the capsid coding region, a total of 1,015
(45.7%) nucleotide positions were variant. The majority of the
mutations in the P1 region (36.5%) were synonymous; however,
at least 45% of the nucleotide substitutions in the VP1-coding
region resulted in amino acid changes in the complete alignment.
A maximum phylogenetic tree constructed from this
alignment with topotypes and the positions of viruses further
investigated using virus neutralization assays is shown in
Figure 2. Phylogenetic resolution of capsid protein sequences
of the SAT3 viruses confirmed five of the six topotypes, each
with its unique geographic distribution. Topotype I included
viruses from South Africa and southern Zimbabwe, topotype II
encompassed viruses from Botswana and western Zimbabwe,
and topotype IV viruses from Zambia.
A pairwise alignment of the capsid proteins of the SAT3
viruses with the corresponding proteins of each reference virus
displayed variation in 28–70 of the amino acid positions, with
most variation in the pairwise alignments with SAT3/BOT/6/98
(46–69 variable residues) (Table 2). No clear correlation was
observed between the number of variable residues and r1-values
to each of the reference viruses (Table 2).
In a complete alignment of the structural proteins, three
regions of notable variability (amino acid entropy >1) were
observed in the VP2 protein at amino acid positions 92–101
(βC-βD loop), 128–138 (βE-βF loop), and 208–217. In the VP3
protein, 23.5% variable amino acid positions were observed and
residues with high entropy (>1) were positioned on the surface-
exposed βE-βF loop at 131, 135, and 139 and in the C-terminus at
residues 219–220. However, several regions with hypervariability
were identified throughout the VP1 protein including: (i) N-
terminal residues 7–16; (ii) the linear amino acid region that
correlates with a T-cell epitope region in serotype O (39), also
in the N-terminus (aa 21–26); (iii) a region in the βB-βC loop (aa
44–55) correlating with O1BFS antigenic site 3 (40); (iv) βD-βE
loop (aa 79–91); (v) βF-βG loop (aa 109–116); (vi) residues 137–
146 and 149–163 of the βG-βH loop; (vii) residues 175–185 and
lastly, (viii) the C-terminus (aa 196–206 and aa 207–216).
Predicting Antigenic Substitutions in the
Outer Capsid Proteins of SAT3 Viruses
Next, we explored the genetic basis of variation expressed in
VN titers. In Figure 3, two heatmaps show the same VN titers
(log10) for 12 viruses (rows) and reference antisera (columns)
raised to three reference viruses organized in two ways: firstly,
where test viruses (rows) are sorted according to the phylogeny
and secondly where test viruses (rows) are sorted according
to a hierarchical clustering of the VN titers. The hierarchical
clustering analysis, also expressed in the dendograms to the right
of the heatmaps, indicated that viruses of the same topotype
did not consistently cluster together on the basis of cross-
reactivity data.
To probe the relationship between VN titers and genetic
differences in greater detail, a sparse hierarchical Bayesian model
was used to test whether substitutions at each non-conserved
amino acid residue, within the VP1, VP2, and VP3 proteins,
were predictors of reduced antigenic cross-reactivity. Residues
would be selected if substitutions between test and reference
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TABLE 3 | Variation within the nucleotide and amino acid sequences of the P1 coding region and deduced polyprotein in a complete alignment to each of the SAT3
reference viruses.
Genome region No. nucleotide
positions aligned
No. variant
nucleotides
Variant nucleotides
(%)
No. amino acid
positions aligned
No. variant amino
acids
Variant amino acids
(%)
VP4 (1A) 258 84 32.5 86 1 1.2
VP2 (1B) 651 276 42.4 217 54 24.8
VP3 (1C) 663 272 41.0 221 52 23.5
VP1 (1D) 651/4 377 57.9 217/8 98 45.2
P1 2220/1 1015 45.6 740/1 205 27.7
FIGURE 2 | Maximum likelihood phylogenetic tree constructed from aligned capsid (P1) nucleotide sequences, with mid-point root. Clades of the phylogeny
corresponding to topotypes are labeled. Viruses tested as antigen in virus neutralization (VN) assays are marked with black circles and reference viruses also used to
generate antiserum for VN assays are marked with red triangles. Internal nodes are labeled with bootstrap values and branch lengths indicate the estimated number of
nucleotide substitutions per site.
virus tended to correlate with lower VN titers. The model also
accounted for other sources of variation in measured VN titers
(Supplementary Figure 1).When compared with themean titers
recorded for each virus and reference virus combination, the
mean difference to these for individual recorded titers was 0.25
log10 titer (maximum 0.89). Some of the variation in recorded
Frontiers in Veterinary Science | www.frontiersin.org 7 September 2020 | Volume 7 | Article 568
Maake et al. FMDV SAT3 Antigenic Variation
FIGURE 3 | Heatmaps of virus neutralization titers (VN) ordered by phylogeny and by hierarchical clustering. The two heatmaps show the same VN titers (log10) for 12
viruses (rows) and reference antisera (columns) raised to reference viruses SAT3/BOT/6/98, SAT3/SAR/1/06, and SAT3/KNP/10/90. To the left, rows of the heatmap
are ordered according to the phylogenetic tree constructed from capsid nucleotide sequences (far left). To the right, rows of the heatmap are ordered according to a
hierarchical clustering algorithm applied to VN titers—a dendogram generated by this algorithm is shown (far right). In both heatmaps, black framing is used to
highlight homologous titers. Highlighted branches of the phylogeny were associated with variation in VN titers using a sparse hierarchical Bayesian model. Branch
color indicates the average effect on titers: green indicates a branch where amino acid substitutions tended to lead to an increase in the VN titer to the three reference
sera pools, while blue branches correlated with decreases in VN titers. No internal branches of the phylogeny tended to correlate with variation in VN titers. Topotype
nomenclature appears next to clades of the phylogeny and alongside each virus name associated with the hierarchical clustering dendogram.
titers was attributed to day-to-day variability in the assay
(Supplementary Figure 1B). The average residual difference
between measured and fitted titers, after accounting for day-to-
day variability was reduced to 0.15 log10 titer (maximum 0.83).
Variable representing amino acid substitutions were tested
alongside terms representing branches of the phylogeny that
could also identify branches leading to individual viruses
or groups of viruses that tended to have higher VN titers,
perhaps as a result of differences in avidity for the cellular
receptor. Four well-supported branches, to which variation
in VN titers mapped, are shown in the phylogenetic tree
in Figure 3. Each branch effect is caused by the combined
effect of one or more residue changes that significantly affect
cross-reactivity between reference and test viruses. Each of
the four identified branches were terminal branches leading
to a single virus, three correlated with low VN titers and
one branch with higher VN titers. The terminal branch for
SAT3/KNP/14/96 significantly accounts (inclusion probability=
0.97) for an increase in antigenic cross-reactivity to all three
reference sera pools. The increase in cross-reactivity reflected
as high VN titers regardless of antisera used and was not
due to a higher virus titer (4.7 ± 0.2 log10/ml) or increased
avidity (AI = 13.95). Three branches in the phylogenetic
tree significantly accounted for a reduction in antigenic cross-
reactivity against all three reference sera pools. These branches
could indicate that the viruses are antigenically distinct, or
that they have low VN titers as a result of increased avidity
for the cellular receptor. One highlighted branch caused a
partitioning of a single topotype (III) from the rest of the
tree (SAT3/ZIM/5/91). The virus SAT3/KNP/1/03, although
genetically similar to SAT3/KNP/10/90 (38 aa differences
in the capsid proteins), is antigenically distinct from the
SAT3/KNP/10/90 and SAT3/SAR/1/06 reference viruses (r1-
value <0.3). Similarly, the separation of SAT3/KNP/2/03 from
the other topotype I viruses was associated with a decrease
in cross-reactivity to the reference sera pools. From our data,
the topotype IV virus SAT3/ZAM/5/93 does not seem to be
antigenically different from the topotype I and II viruses.
The three branches in the phylogeny in Figure 3 identified
as correlating with reduced VN titers lead to single viruses that
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TABLE 4 | Amino acid positions in the SAT3 capsid proteins with substitutions explaining a decrease in the VN titers.
Capsid protein and
amino acid position in
the SAT3 alignment*
Serotype(s) where
residue is antigenic
Antigenically distinct
amino acids
Inclusion probability Impact of
substitutions on
cross-reactivity
(log10 VN titer)
VP1 83/VP1 164 None/O3 L-Q, C-R 0.88 −1.2
VP2 134/VP3 168 SAT2, O1,2/None K-Q-T, F-Y 0.42 −0.6
VP1 201 T-V-A-R 0.32 −0.22
VP2 209 Y-F-H 0.30 −0.37
Substitutions at each amino acid position (or combination of positions sharing the same pattern of substitution across viruses in the VN dataset) was tested in a Bayesian model with an
indicator variable determining inclusion (1) or exclusion (0) from the model and a coefficient or effect size. The inclusion probability represents the posterior mean value of the indicator
variable and the level of support. Model fitting indicated inclusion probabilities above 0.25 have been reasonably well-supported. For each position(s), the conditional effect size is the
estimated average impact on VN titers when substitution(s) between test and reference viruses are present.
*Where more than one amino acid appears in a row, this indicates the pattern of substitution at these residues to be identical in the dataset.
are potentially antigenically distinct due to amino acid residue
substitutions in the capsid protein. Amino acid substitutions
mapping to each of these branches were identified. The branch
leading to the virus SAT3/ZIM/5/91 correlated with 13 residue
substitutions in the outer capsid proteins, while the branch
leading to SAT3/KNP/1/03 correlated with substitutions at
five residue positions, therefore there were several candidate
substitutions in these two instances. Only two amino acid
substitutions, VP1 L83Q and C164R, mapped to the terminal
branch separating SAT3/KNP/2/03 from the rest of the tree;
in fact, VP1 83L and 164C are conserved across each of the
other 11 viruses in the dataset. Therefore, the substitutions
VP1 L83Q and C164R are plausible candidates for causing a
reduction in antigenic cross-reactivity. Of these two residues,
VP1 164 aligns to a residue that is part of a known epitope in
serotype O (17).
Across the phylogeny, three other terms representing amino
acid substitutions were identified as correlating with reduced
VN titers (Table 4) (model selection indicated terms with
posterior inclusion probability>0.25 to have a reasonable level of
support). The first of these terms with greatest support (inclusion
probability = 0.88) represented simultaneous substitutions at
VP2 residue 134 [Lys (10), Gln (1), Thr (1)] and VP3 168
[Phe (10), Tyr (2)], which only substituted together in this
dataset and therefore could not be distinguished. The positions
in the phylogeny where these residues were both substituted
were terminal branches leading to viruses SAT3/KNP/1/03 (VP2
K134Q and VP3 F168Y) and SAT3/ZIM/5/91 (VP2 K134Q and
VP3 F168Y), both of which had low titers against each of the
three antisera used. Of these two residues, the VP2 residue 134
has been identified as being part of an epitope for serotype O
and SAT2 viruses (17, 29, 40). Finally, genetic terms associated
with VP1 residue 201 [Thr (8), Val (2), Ala (1), Arg (1)], which
forms part of the VP1 C-terminus, and VP2 residue 209 [Tyr (9),
Phe (2), His (1)] were also identified as potentially antigenically
important with substitution, though with reduced support. The
location of the latter six residues can be resolved on the predicted
structure of serotype SAT3 capsid and is shown in Figure 4.
DISCUSSION
The present study confirms the close antigenic relationship
between SAT3 viruses in southern Africa using in vitro cross-
reactivity studies. We then used the antigenic variability data and
corresponding genetic and structural data to predict naturally
occurring amino acid positions that correlated with antigenic
changes. Knowledge of the molecular mechanisms of antigenic
evolution are essential to implement systematic approaches to
predict protection offered by reference vaccine viruses during
prophylactic vaccination in endemic regions or emergency
vaccination during an outbreak.
Of the three SAT serotype FMD viruses that occur in southern
Africa, SAT3 has the most restricted distribution and outbreaks
in livestock are only observed sporadically every 8–15 years
(12). A comparison of the genetic diversity within the VP1
coding region of SAT3 viruses, collected between 1965 and
1999 in southern Africa and South-western Uganda, divided the
SAT3 viruses into six topotypes (12). Findings from our study,
using the complete P1 capsid-coding sequences of SAT3 viruses
recovered between 1990 and 2008, substantiated the topotype
definitions for SAT3 viruses in southern Africa. Viruses recovered
from buffalo in the Kruger National Park, South Africa, and
southern Zimbabwe clustered together based on the capsid-
coding sequences. Topotype I lineage viruses in South Africa are
maintained in buffalo from the Kruger National Park with an
incursion every 8–15 years to cattle neighboring this endemic
area. Topotype II viruses include viruses from Botswana and
western Zimbabwe, while virus isolates from Zambia clustered
separately in the phylogenetic tree, defined as topotype IV.
The single isolate from northern Zimbabwe was genetically
distinct and correlated to topotype III, as described by Bastos
et al. (12).
The in vitro cross-reactivity analysis of SAT3 viruses was
notably high, i.e., 67, 92, and 100% of the SAT3 viruses
reacted strongly (r1-values ≥0.3) to the SAT3/KNP/10/90,
SAT3/SAR/1/06, and SAT3/BOT/6/98 reference antisera. The
implication is that, in a case of a cattle outbreak, vaccines
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FIGURE 4 | (A) Schematic diagram of the capsid proteins showing the amino acid variation in a complete alignment and the relative positions of amino acid
substitutions explaining a decrease in the VN titers. (B) A model of the FMDV SAT3 pentamer showing the amino acid residues that correspond to branch formation in
a phylogenetic tree and a decline in cross-reactivity in VNTs. The inferred 3-D structure were generated using the SAT1 virus (protein data bank ID: 2WZR) as a
template and the structural model rendered by Pymol v 1.8 (DeLano Scientific LLC). The capsid proteins VP1, VP2, and VP3 are shown in blue, green, and pink,
respectively, while the exposed amino acid variants are indicated by red spheres. The 3-fold axis is depicted by the black triangles. The pore, located at the 5-fold axis
of the capsid (black pentagon), is shown in the middle of the structure. The black lines connect the residues that changed simultaneously.
consisting of any one of the three reference viruses will provide
sufficient protection. Moreover, some of the SAT3 viruses reacted
stronger to the reference sera thanwith the homologous virus (r1-
value>1). Particularly, the SAT3/SAR/1/06 and SAT3/BOT/6/98
antisera were highly cross-reactive to the test viruses as indicated
by r1-values >1. Similar results where heterologous cross-
reactivity was higher than homologous reactivity have been
documented with serotype A FMDV (17, 41). These findings
indicate (i) similarities in shared epitopes between the reference
and the field viruses, (ii) the reference viruses elicited broadly
reactive antibodies in cattle, or (iii) antibodies with high
avidity to SAT3 viruses were present. In an attempt to further
investigate factors influencing this cross-reactivity, an avidity
ELISA was performed to assess and characterize this high
heterologous cross-reactivity (32, 42). An increased avidity of
SAT3/BOT/6/98 antisera in binding to heterologous viruses
(i.e., SAT3/KNP/10/90 and SAT3/SAR/14/01) could explain the
higher neutralization titers observed for these viruses. Although
higher avidity indexes have been linked to high neutralization
titer, this is not always the case. Other factors, such as antibody
class or IgG isotype, may also play a role.
The high amino acid variation of the VP1 protein (45%
variable residue positions), compared to the other capsid
proteins, indicates that VP1 is likely to be under immunologic
pressure. Genetic changes and selection of antigenic variants are
generally accepted to occur in persistently infected wildlife (8, 43,
44). The majority of variable residues are limited to particular
surface-exposed structural loops and changes elsewhere may be
under stringent structural and selective constraints (45). The fact
that most of the SAT3 capsid amino acid positions with high
entropy were identified in the VP1 protein emphasizes that this
protein has a major immunogenic role and it also modulates
the antigenic variability of the virus. Previous crystallographic
studies and structure-based epitope predictions revealed that
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VP1 is important to interact with antibodies, especially the βG-
βH loop and residues toward the 5-fold axis of the capsid (46, 47).
The immunological role of an additional K residue within the βD-
βE loop of the VP1 protein of one isolate is unknown. Although
less variation was identified in the VP2 and VP3 proteins, these
proteins still play an important role in antigenic variation of
FMDV. A conformational epitope comprising of residues from
the VP2 and VP3 capsid proteins and spanning the 3-fold axis,
was also present (47–49). This emphasizes that cross-reactivity
is influenced by main, variable capsid amino acid residues and
may be affected more by residue interactions rather than residue
changes (48, 50–52).
We identified substitutions with a profound effect on
antigenic variation that were likely associated with immune
evasion. Variation at two residue positions in the VP1 protein,
residues 83 and 169, were associated with reduced titers
against SAT3/KNP/10/90 and SAT3/SAR/1/06 antisera. The VP1
residues 83 and 169 are located at opposite sides of an elevated
plateau on the capsid surface, with residue 83 forming an exposed
cluster around the 5-fold axis and residue 169 located at the
C-terminal base of the VP1 βG-βH loop. The VP1 residue 83
of SAT2 viruses has been found to be accessible to interact
with glycosaminoglycan (18), confirming its accessibility to
interact with cellular receptors. Similarly, residues 134 in VP2
and 168 in VP3 together, were associated with an antigenic
effect for SAT3/KNP/1/03 and SAT3/ZIM/5/91. It is reasonable
to hypothesize that the two residues together function as a
conformational epitope, however, the same variation in VN titer
is equally well-explained by VP2 K134Q/T substitution. The VP2
residue 134 has been described as an antigenic site for serotypes
O and SAT2, and is located on a surface exposed structural loop
and is structurally more favorable to contribute to variation in
antigenicity (48, 49). Residue 168 in VP3 has not been described
to play a role in antigenicity before. Both residues are located in
a shallow, structural depression, located at the junction between
the three major capsid proteins VP2, VP3, and VP1 (Figure 4).
Two other residues have also been associated with antigenic
variation in SAT3 viruses, one in the C-terminal end of VP2
and the other located on the C-terminus of VP1. Only the VP1
C-terminus residue corresponds to a described antigenic site in
serotype O (40, 48).
Amino acids that are important for the antigenicity of SAT1
viruses have been identified at positions 135 or 71 or 76 of VP3;
72 of VP2 and 181 of VP1; and 111 of VP1 using MAb resistant
(mar) mutants (49). Similarly, residues 72 or 79 of VP2; 158 of
VP1; and 154 or 158 in the βG-βH loop of VP1 of SAT2 viruses
have been shown to interact with MAbs or affect the antigenicity
of the virus (29, 49). At least five neutralizing antigenic sites,
involving the three outer-capsid proteins, have been identified
for serotype O viruses. The most prominent surface exposed
structure, the βG-βH loop of VP1, and the C-terminus of VP1
have been shown to contribute to antigenic site 1 of serotype
O viruses, with critical residues at position 144, 148, 154, and
208 (53–56). Amino acid residues at positions 70–73, 75, 77,
and 131 of VP2, 56 and 58 of VP3, and 43 and 44 of VP1
contributes to the remaining antigenic site for serotype O (56).
Mar-mutants identified three antigenic sites within the VP1, VP2,
and VP3 proteins for serotype A viruses A10, A12, and A22 with
residue positions 148, 149, 152, 153, 168, and 205 within VP1
important for antigenicity (57–60). Here, for the first time, we
have mapped four unique amino acid regions associated with
antigenic changes in SAT3 viruses. In two of these regions two
amino acid residues changed together to affect the antigenicity of
the virus, i.e., residues 83 and 169 of VP1 and residues 134 in VP2
and 168 in VP3.
We have successfully used phenotypic data, combined with
genotypic and structural information in our mathematical
models to delineate antigenic sites for SAT3 viruses. The analysis
of antigenic differences in outbreak viruses is critical to allow
proper vaccine selection for effective control or the design
of vaccine antigens tailored for specific geographic localities,
using reverse genetics. This work could be further validated
using a reverse genetics approach to immune-dampen specific
residues to identify its antigenic significance. We anticipate
that identifying unique residues associated with a change in
cross-reactivity will contribute to improved vaccine development
and assessment.
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Supplementary Figure 1 | Variability in virus neutralization titers (log10) for 12
viruses tested using antisera raised to reference strains SAT3/BOT/6/98,
SAT3/SAR/1/06, and SAT3/KNP/10/90 (N = 198). (A) Histogram of absolute
differences in measured titers and the mean log10 titer recorded for each virus and
reference strain combination. (B) Violin plot showing posterior model estimates of
the variation in VN titers that can be attributed to variability between experiments
carried out on 15 different days. Each violin represents 1,600 values sampled from
eight independent MCMC chains. Black horizontal lines represent median values.
(C) Histogram showing residuals from a model fitted to VN titers—each residual is
the absolute difference between a measured titer adjusted for day-to-day variation
and the fitted, underlying titer for the particular virus and reference strain
combination. (D) Scatterplot showing measured VN titers (black circles) and those
same VN titers adjusted to account for day-to-day variability (red crosses) plotted
against the fitted, underlying titer for a particular virus and reference
strain combination.
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